Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
7.43
+0.03 (0.41%)
Aug 14, 2025, 11:50 AM - Market open

Silexion Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2013 FY 2012
Period Ending
Dec '24 Dec '23 Dec '13 Dec '12
Net Income
-16.44-4.94-1.36-0.94
Depreciation & Amortization
0.030.0500
Loss (Gain) From Sale of Assets
0.02-0--
Stock-Based Compensation
5.860.130.420.04
Other Operating Activities
3.720.15--
Change in Accounts Receivable
--0.06-0.1
Change in Accounts Payable
0.610.080.020.06
Change in Other Net Operating Assets
-2.190.010.050.03
Operating Cash Flow
-8.4-4.53-0.79-0.91
Capital Expenditures
-0.02-0.01-0.01-0
Sale of Property, Plant & Equipment
-0.08--
Investment in Securities
-0.51--
Other Investing Activities
---0.01-0.03
Investing Cash Flow
-0.020.57-0.02-0.03
Long-Term Debt Repaid
-0.25---
Net Debt Issued (Repaid)
-0.25---
Issuance of Common Stock
3.05--1.72
Other Financing Activities
2.3---
Financing Cash Flow
5.10.52-1.72
Foreign Exchange Rate Adjustments
-0.06-0.23--
Net Cash Flow
-3.38-3.66-0.810.78
Free Cash Flow
-8.42-4.54-0.8-0.91
Free Cash Flow Per Share
-202.40---
Cash Interest Paid
0.03---
Levered Free Cash Flow
-2.41--0.31-
Unlevered Free Cash Flow
-2.39--0.3-
Change in Working Capital
-1.580.090.13-0.02
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q